US biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) announced on Tuesday that GW University Hospital, UC Irvine and Northwell Health have provided written approval to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 intended for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
The Phase 2a dose-ranging study is intended to assess the efficacy, safety and tolerability of topical HT-001 intended for the treatment of skin toxicities related to EGFRi.
Hoth Therapeutics chief executive officer Robb Knie said: "We are very pleased to have received approval from these three world class medical centres for our FIH clinical trial. We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001 and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments."
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen